A New Opioid Substance in Human Spinal Fluid Was Linked to Pain Status
A newly characterized opioid substance (Peak B) in human spinal fluid produced pain relief 10× more potent than morphine per weight, with both mu and delta receptor activity.
Quick Facts
What This Study Found
Human cerebrospinal fluid (CSF) from pain-free surgery patients contained Peak B at a concentration equivalent to about 1.4 picomoles of morphine per milliliter.
Injected into mouse brains, Peak B produced dose-dependent pain relief at 0.06 and 0.12 picomoles of morphine equivalents. Naloxone (an opioid blocker) reversed this effect, confirming it works through opioid receptors.
In a muscle tissue assay (mouse vas deferens), Peak B's activity was blocked by low naloxone concentrations but not high ones. This unusual pattern suggests it interacts with opioid receptors differently than known opioids.
Most surprisingly, Peak B was not destroyed by trypsin or alpha-chymotrypsin, protein-digesting enzymes that break down all known opioid peptides. This means Peak B is either not a peptide or has an unusual structure that protects it from enzymes.
Key Numbers
How They Did This
Peak B was isolated from human CSF using gel filtration chromatography. Pain relief was tested in mice by intracerebroventricular injection with hot-plate and tail-flick tests. Opioid specificity confirmed with naloxone. Mouse vas deferens bioassay tested tissue-level effects. Enzyme resistance was tested with trypsin and chymotrypsin.
Why This Research Matters
The human spinal fluid contains opioid substances we have not yet identified. Peak B correlates with pain status in chronic pain patients and resists enzymatic breakdown. If characterized, it could lead to new types of painkillers that last longer because they resist normal degradation.
The Bigger Picture
The human body may contain undiscovered natural painkillers more potent than morphine. Identifying and characterizing these could lead to new pain treatments with fewer side effects than synthetic opioids.
What This Study Doesn't Tell Us
Peak B was not fully characterized or identified. The active component could be a modified peptide, a non-peptide opioid, or a mixture. The mouse pain tests may not predict human effects. The number of CSF samples was small.
Questions This Raises
- ?What is the exact chemical identity of Peak B?
- ?Could synthetic analogs of Peak B serve as safer painkillers?
- ?Why is Peak B related to chronic pain patient status?
Trust & Context
- Key Stat:
- 10× more potent than morphine By weight, when injected into mouse brains
- Evidence Grade:
- Preliminary in-vitro/animal study characterizing a novel substance — identity not fully determined.
- Study Age:
- Published in 1987 — the full identity of Peak B remains an area of research.
- Original Title:
- Partial characterization of a novel endogenous opioid in human cerebrospinal fluid.
- Published In:
- Life sciences, 41(23), 2535-45 (1987)
- Authors:
- Miller, B E, Lipman, J J, Byrne, W L
- Database ID:
- RPEP-00054
Evidence Hierarchy
Frequently Asked Questions
What is Peak B?
A partially characterized opioid substance found in human spinal fluid. It is smaller than enkephalins, works through mu and delta opioid receptors, and is more potent than morphine by weight.
Why is this substance important for pain treatment?
If fully identified, Peak B could serve as a template for designing new painkillers that mimic natural brain chemistry, potentially with fewer side effects and addiction risk than synthetic opioids.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00054APA
Miller, B E; Lipman, J J; Byrne, W L. (1987). Partial characterization of a novel endogenous opioid in human cerebrospinal fluid.. Life sciences, 41(23), 2535-45.
MLA
Miller, B E, et al. "Partial characterization of a novel endogenous opioid in human cerebrospinal fluid.." Life sciences, 1987.
RethinkPeptides
RethinkPeptides Research Database. "Partial characterization of a novel endogenous opioid in hum..." RPEP-00054. Retrieved from https://rethinkpeptides.com/research/miller-1987-partial-characterization-of-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.